Compare TFPM & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFPM | BIO |
|---|---|---|
| Founded | 2016 | 1952 |
| Country | Canada | United States |
| Employees | N/A | 7450 |
| Industry | Precious Metals | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 7.1B |
| IPO Year | 2022 | N/A |
| Metric | TFPM | BIO |
|---|---|---|
| Price | $30.31 | $262.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $35.33 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 535.0K | 235.7K |
| Earning Date | 02-18-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.66 | $2.74 |
| Revenue Next Year | N/A | $3.05 |
| P/E Ratio | $35.57 | ★ $9.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.72 | $211.43 |
| 52 Week High | $41.70 | $343.12 |
| Indicator | TFPM | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 27.76 | 40.24 |
| Support Level | $27.14 | $239.33 |
| Resistance Level | $33.48 | $289.61 |
| Average True Range (ATR) | 1.46 | 7.46 |
| MACD | -1.01 | 0.44 |
| Stochastic Oscillator | 4.24 | 19.99 |
Triple Flag Precious Metals Corp is a streaming and royalty company focused on precious metals. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Mexico, Mongolia, Peru, South Africa, and the United States. Its diversified portfolio of streams and royalties comprises long-life mining assets, including the Northparkes copper-gold mine in Australia, the Cerro Lindo polymetallic mine in Peru, the Fosterville gold mine in Australia, the Buritica gold mine in Colombia, and the Impala Bafokeng Operations in South Africa among others. A majority of its revenue is derived through its interests in various gold streams. Geographically, the company derives maximum revenue from Australia, followed by Peru and other regions.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.